Ursula Medeiros Araujo de Matos

Dr. Ursula Medeiros Araujo de Matos

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2021 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
LQLaiana Quagliato
Laiana Quagliato
UMUrsula Medeiros Araujo de Matos
Ursula Medeiros Araujo de Matos
ANAntonio E Nardi
Antonio E Nardi
Maternal immune activation (MIA) during pregnancy is recognized as an etiological risk factor for various psychiatric disorders, such as schizophrenia, major depressive disorder, and autism. Prenatal immune challenge may serve as a “disease primer” for alteration of the trajectory of fetal brain development that, in combination with other genetic and environmental factors, may ultimately result in the emergence of different psychiatric conditions. However, the association between MIA and an offspring’s chance of developing anxiety disorders is less clear. To evaluate the effect of MIA on offspring anxiety, a systematic review and meta-analysis of the preclinical literature was conducted. We performed a systematic search of the PubMed, Web of Science, PsycINFO, and Cochrane Library electronic databases using the PRISMA and World Health Organization (WHO) methodologies for systematic reviews. Studies that investigated whether MIA during pregnancy could cause anxiety symptoms in rodent offspring were included. Overall, the meta-analysis showed that MIA induced anxiety behavior in offspring. The studies provide strong evidence that prenatal immune activation impacts specific molecular targets and synapse formation and function and induces an imbalance in neurotransmission that could be related to the generation of anxiety in offspring. Future research should further explore the role of MIA in anxiety endophenotypes. According to this meta-analysis, MIA plays an important role in the pathophysiological mechanisms of anxiety disorders and is a promising therapeutic target.

1 December 2021 in Journal of Affective Disorders
Verified
Journal Article
Closed access
LQLaiana Quagliato
Laiana Quagliato
DCDanielle A. Coelho
Danielle A. Coelho
UMUrsula Medeiros Araujo de Matos
Ursula Medeiros Araujo de Matos
ANAntonio E Nardi
Antonio E Nardi

1 April 2021 in Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
CSCamila Barros Melgaço da Silva
Camila Barros Melgaço da Silva
BVBernardo Vicari Do Valle
Bernardo Vicari Do Valle
UMUrsula Medeiros Araujo de Matos
Ursula Medeiros Araujo de Matos
YAYasmin Amaral
Yasmin Amaral
MMMaria E. Moreira
Maria E. Moreira
AVAlan Araújo Vieira
Alan Araújo Vieira

4 May 2026 in Baylor University Medical Center Proceedings
Verified
Journal Article
Closed access
UMUrsula Medeiros Araujo de Matos
Ursula Medeiros Araujo de Matos
EIEduardo Dan Itaya
Eduardo Dan Itaya
PMPatrick Froelich Meldola
Patrick Froelich Meldola
PDPedro Luiz Lage Bodour Danielian
Pedro Luiz Lage Bodour Danielian
SKSwarup Kumar
Swarup Kumar
RVRitika Vankina
Ritika Vankina
Cancer-associated thrombosis is a major cause of morbidity and mortality in patients with cancer and is associated with a high risk of both recurrent venous thromboembolism (VTE) and bleeding. Although extended anticoagulation reduces the risk of recurrent VTE by more than 80%, full-dose therapy may increase bleeding complications, potentially offsetting its benefit in this population. Reduced-dose direct oral anticoagulants (DOACs) have therefore been proposed as a safer long-term treatment option. We conducted a systematic review and meta-analysis of randomized controlled trials comparing reduced-dose DOACs with standard-dose regimens for extended VTE treatment in cancer patients. Outcomes included recurrent VTE, major bleeding, clinically relevant nonmajor bleeding, all-cause mortality, and composite bleeding, with pooled odds ratios calculated using random-effects models. Five randomized trials involving 2709 patients were included. Recurrent VTE rates were comparable between reduced-dose and standard-dose DOACs. Reduced-dose therapy was associated with a significant reduction in clinically relevant nonmajor bleeding and composite bleeding. While major bleeding occurred less, the difference was not statistically significant. Overall, reduced-dose DOACs demonstrated similar efficacy in preventing recurrent VTE while offering an improved bleeding profile, supporting their potential role in long-term management of cancer-associated thrombosis, though larger prospective studies are needed to define optimal dosing strategies.

27 March 2026 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
UMUrsula Medeiros Araujo de Matos
Ursula Medeiros Araujo de Matos
WTWan Ying Tan
Wan Ying Tan
VFVictoria Forbes
Victoria Forbes

29 May 2026 in Baylor University Medical Center Proceedings
Verified
Journal Article
Closed access
UMUrsula Medeiros Araujo de Matos
Ursula Medeiros Araujo de Matos
MSMoana Divina da Silva Santiago
Moana Divina da Silva Santiago
HCHenrique Guimaraes Barbosa Coelho
Henrique Guimaraes Barbosa Coelho
FKFatih Kaner
Fatih Kaner
NRNathaniel Robinson
Nathaniel Robinson